Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1. Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)

Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) T echnology appraisal guidance Published: 7 October 2020 www.nice.org.uk/guidance/ta652 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice (...) -of- rights).Contents Contents Advice 3 Information 3 Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) (TA652) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 3Advice Advice NICE is unable to make a recommendation about the use in the NHS of alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

2. Multicomponent Interventions to Improve Screening for Breast, Cervical or Colorectal Cancer

Multicomponent Interventions to Improve Screening for Breast, Cervical or Colorectal Cancer Oregon Health Authority : Evidence-based Reports Blog : Health Evidence Review Commission : State of Oregon menu Toggle Main Menu Main Navigation close search Search search Submit You are here: Evidence-based Reports Blog menu Site Navigation Evidence-based Reports Blog Full Width Column 1 Select Ablation for Atrial Fibrillation Acellular Dermal Matrix for Post-Mastectomy Breast Reconstruction Compliance (...) ={ListId}'); return false;} if(pageid == 'audit') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/Reporting.aspx' +'?Category=Auditing&backtype=item&ID={ItemId}&List={ListId}'); return false;} if(pageid == 'config') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/expirationconfig.aspx' +'?ID={ItemId}&List={ListId}'); return false;}}, null); 0x0 0x1 ContentType 0x01 898 BlogTopic Multicomponent Interventions to Improve Screening for Breast, Cervical or Colorectal Cancer

2020 Oregon Health Evidence Review Commission

3. Guidance for the management of early breast cancer: Recommendations and practice points

Consider further surgery (re-excision or mastectomy, as appropriate) after breast-conserving surgery where there is invasive cancer and/or DCIS within 2mm of but not at the radial margins (>0mm and <2 mm). Practice Point In patients with Paget’s disease of the nipple, perform breast imaging prior to surgery to exclude underlying breast malignancy. Recommendation In patients with Paget’s disease of the nipple with or without underlying breast cancer, offer breast-conserving surgery with removal (...) or armpit. The scope of this guidance covers the management of early breast cancer in women and men. The scope does not include the management of ductal carcinoma in situ (DCIS) which is non-invasive, or the management of advanced or metastatic cancer. Guidance is included for the management and care of early breast cancer across the patient journey from the point of breast cancer diagnosis, including treatment planning and information and support for patients before treatment, treatment delivery

2020 Cancer Australia

4. Guidance for the management of early breast cancer: Methods

of early breast cancer. A separate resource is currently being developed for consumers by the Breast Cancer Network Australia (BCNA), with support from Cancer Australia. 2.2 Scope Early breast cancer is considered in the current context to be: ‘invasive breast cancer that is contained in the breast and may or may not have spread to lymph nodes in the breast or armpit. Some cancer cells may have spread outside the breast and armpit area but cannot be detected’. This excludes ductal carcinoma in situ (...) to recommendations – e.g. GRADE, SIGN, NHMRC • Breast cancer subtype(s) – early breast cancer, inflammatory breast cancer, Paget’s disease, patients at high-risk of breast cancer, patients BRCA1/2 positive • Main aspect(s) of care covered (referred to during development as ‘topics’) – e.g. surgery, radiotherapy, systemic therapy, follow up, survivorship care, etc. Key characteristics of all initially identified CPGs are provided in Appendix F. 3.2.3 Selection of guidelines Thirty-eight of the 84 identified CPGs

2020 Cancer Australia

5. Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer: An Individual Participant Data and Trial-Level Meta-analysis (Full text)

a shorter duration with 1 year of trastuzumab as adjuvant treatment, and include patients with early breast cancer. Data extraction and synthesis: Individual patient data for disease-free survival (DFS) and overall survival (OS) were extracted from published survival curves of included RCTs; DFS and OS curves for each trial and the combined population were reconstructed. The DFS and OS hazard ratios (HRs) were estimated from the reconstructed survival curves as well as published estimates. The HR (...) Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer: An Individual Participant Data and Trial-Level Meta-analysis Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer: An Individual Participant Data and Trial-Level Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several

2020 EvidenceUpdates PubMed abstract

6. 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5) (Full text)

Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea N.U. Lin Affiliations Susan Smith Center for Women's CancersBreast Oncology Center, Dana-Farber Cancer Institute, Boston, USA S.A. Mertz Affiliations Metastatic Breast Cancer Network, Inverness, USA S. Neciosup Affiliations Department of Medical Oncology, National Institute of Neoplastic Diseases, Lima, Peru B.V. Offersen Affiliations Department of Oncology, Aarhus University Hospital, Aarhus (...) general guidelines To date, the removal of the primary tumour in patients with de novo stage IV breast cancer has not been associated with prolongation of survival, with the possible exception of the subset of patients with bone-only disease. However, it can be considered in selected patients with controlled systemic disease, particularly to improve QoL, always taking into account the patient’s preferences. Of note, some studies suggest that surgery is only valuable if performed with the same

2020 European Society for Medical Oncology PubMed abstract

7. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 tria (Abstract)

week for 12 weeks followed by doxorubicin at 60 mg/m2 and cyclophosphamide at 600 mg/m2 every 2 weeks for 8 weeks, which was then followed by surgery. Stratification was by clinical breast cancer stage and programmed cell death ligand 1 (PD-L1) status. Co-primary endpoints were pathological complete response in all-randomised (ie, all randomly assigned patients in the intention-to-treat population) and PD-L1-positive (ie, patients with PD-L1-expressing tumour infiltrating immune cells covering ≥1 (...) Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 tria Preferred neoadjuvant regimens for early-stage triple-negative breast cancer (TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy. IMpassion031 compared efficacy and safety of atezolizumab versus placebo combined

2020 Lancet

8. Pertuzumab (Perjeta) - In combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC) at high risk of recurrence.

patients were allowed to receive concomitant radiotherapy and/or adjuvant hormone therapy, if indicated, according to standard therapy. 2, 3 The primary outcome was invasive disease-free survival (IDFS), measured in the intention to treat population and defined as the time from randomisation until the date of the first occurrence of one of the following events: ? ipsilateral invasive breast tumour recurrence (an invasive breast cancer involving the same breast parenchyma as the original primary lesion (...) receptor has been identified as an important target for the treatment of breast cancer due to its involvement in regulating cell growth, survival, and differentiation. Amplification and/or overexpression of HER2 occurs in around 15% to 20% of breast cancers and is associated with increased tumour aggressiveness, higher rates of recurrence, and increased mortality. 3 The submitting company has requested that SMC considers pertuzumab when positioned for use in patients with lymph node-positive disease

2020 Scottish Medicines Consortium

9. Trastuzumab for treating HER2-positive breast and gastric cancers

Trastuzumab for treating HER2-positive breast and gastric cancers 1 Driving better decision-making in healthcare Trastuzumab for treating HER2-positive breast and gastric cancers Technology Guidance from the MOH Drug Advisory Committee Published on 1 September 2020 Guidance recommendations The Ministry of Health’s Drug Advisory Committee has recommended: ? Trastuzumab biosimilar (Ogivri) 440 mg powder for IV injection for treating: ? HER2-positive early or metastatic breast cancer, or ? HER2 (...) breast and gastric cancers. The Agency for Care Effectiveness conducted the evaluation in consultation with clinical experts from the public healthcare institutions. Published clinical and economic evidence for Herzuma and Ogivri was considered in line with their registered indications. The evidence was used to inform the Committee’s deliberations around four core decision-making criteria: ? Clinical need of patients and nature of the condition; ? Clinical effectiveness and safety of the technology

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

10. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT (Full text)

Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website (...) search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This trial showed that in patients with HER2-positive early breast cancer, 6 months' adjuvant trastuzumab was non-inferior to 12 months', with less cardiac toxicity and fewer severe adverse events. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , , , , & . Helena Earl 1, 2, 3, * , Louise Hiller 4 , Anne-Laure Vallier 5 , Shrushma Loi 4

2020 NIHR HTA programme PubMed abstract

11. Alpelisib (Piqray) - metastatic breast cancer

Alpelisib (Piqray) - metastatic breast cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2020 Health Canada - Drug and Health Product Register

12. Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study. (Abstract)

Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study. Surveillance with annual mammography and breast magnetic resonance imaging (MRI) is recommended for female survivors of childhood cancer treated with chest radiation, yet benefits, harms, and costs are uncertain.To compare the benefits, harms, and cost-effectiveness of breast cancer screening strategies in childhood cancer (...) survivors.Collaborative simulation modeling using 2 Cancer Intervention and Surveillance Modeling Network breast cancer models.Childhood Cancer Survivor Study and published data.Women aged 20 years with a history of chest radiotherapy.Lifetime.Payer.Annual MRI with or without mammography, starting at age 25, 30, or 35 years.Breast cancer deaths averted, false-positive screening results, benign biopsy results, and incremental cost-effectiveness ratios (ICERs).Lifetime breast cancer mortality risk without screening

2020 Annals of Internal Medicine

13. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. (Full text)

, maximum 18.90 years, interquartile range 7.0-10.6) no statistically significant difference was found for local recurrence-free survival (hazard ratio 1.13, 95% confidence interval 0.91 to 1.41, P=0.28), mastectomy-free survival (0.96, 0.78 to 1.19, P=0.74), distant disease-free survival (0.88, 0.69 to 1.12, P=0.30), overall survival (0.82, 0.63 to 1.05, P=0.13), and breast cancer mortality (1.12, 0.78 to 1.60, P=0.54). Mortality from other causes was significantly lower (0.59, 0.40 to 0.86, P=0.005 (...) Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose during lumpectomy, can effectively replace postoperative whole breast external beam radiotherapy for early breast cancer.Prospective, open label, randomised controlled clinical trial.32 centres in 10 countries

2020 BMJ PubMed abstract

14. Effectiveness of four types of bandages and kinesio-tape for treating breast-cancer-related lymphoedema: a randomized, single-blind, clinical trial

Effectiveness of four types of bandages and kinesio-tape for treating breast-cancer-related lymphoedema: a randomized, single-blind, clinical trial Effectiveness of four types of bandages and kinesio-tape for treating breast-cancer-related lymphoedema: a randomized, single-blind, clinical trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) -tape for treating breast-cancer-related lymphoedema: a randomized, single-blind, clinical trial , , , , , Affiliations Expand Affiliations 1 Physiotherapy Department, Physiotherapy in Women's Health Research Group, Faculty of Physiotherapy, University of Alcalá, Alcalá de Henares, Madrid, Spain. 2 Faculty of Physiotherapy and Nursing, University of Castilla-La Mancha, Toledo, Spain. PMID: 32580577 DOI: Item in Clipboard Effectiveness of four types of bandages and kinesio-tape for treating breast

2020 EvidenceUpdates

15. Alpelisib (Piqray) - postmenopausal women and men with breast cancer

, alpelisib, works by blocking the activity of the abnormal PI3K, thereby reducing the growth and spread of the cancer. Piqray (alpelisib) EMA/298596/2020 Page 2/2 What benefits of Piqray have been shown in studies? A main study involved 340 patients with advanced breast cancer with a PIK3CA mutation in whom hormone treatment had not worked or the cancer had come back. Patients treated with Piqray in combination with fulvestrant lived on average for 11 months without their disease getting worse compared (...) are greater than its risks and it can be authorised for use in the EU. Piqray used with fulvestrant increased the time before the disease got worse in patients with HR-positive and HER2-negative breast cancer that is advanced or has spread. In terms of the medicine’s side effects, the main concern is high blood sugar levels which may lead to diabetes and gut problems but the Agency has recommended measures to manage this. What measures are being taken to ensure the safe and effective use of Piqray

2020 European Medicines Agency - EPARs

16. Trastuzumab (Zercepac) - breast cancer, gastric cancer

of Zercepac and why it is authorised in the EU What is Zercepac and what is it used for? Zercepac is a cancer medicine used to treat the following conditions: • early breast cancer (when the cancer has spread within the breast or to the lymph nodes [‘glands’] under the arm but not to other parts of the body) after surgery, chemotherapy (medicines to treat cancer), and radiotherapy (treatment with radiation) if applicable. It can also be used earlier in treatment, in combination with chemotherapy (...) a week or once every 3 weeks for breast cancer, and once every 3 weeks for gastric cancer. For early breast cancer, treatment is given for a year or until the disease comes back, and for metastatic breast or gastric cancer, treatment is continued for as long as it remains effective. The dose depends on the patient’s body weight, on the condition being treated and on whether Zercepac is given every week or every 3 weeks. The infusion may cause allergic reactions, so the patient should be monitored

2020 European Medicines Agency - EPARs

17. Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer – Update

Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer – Update Estrogen and Progesterone Receptor… | College of American Pathologists Group CAP_logo_rgb[1] User Toggle Navigation Menu Search Down Arrow Down Arrow Down Arrow Down Arrow Down Arrow Down Arrow Down Arrow Estrogen and Progesterone Receptor Testing in Breast Cancer Guideline Update Estrogen and Progesterone Receptor Testing in Breast Cancer Guideline Update Background An expert panel was convened (...) to evaluate evidence in an update and reaffirmation of the 2010 “ASCO/CAP Guideline Recommendations for Immunohistochemical (IHC) Testing of Estrogen and Progesterone Receptors (ER/PgR) in Breast Cancer.” Notably the “ ” differences impact pathologists and patients, including: A new recommendation for laboratories to establish a specific standard operating procedure to ensure the validity of low positive (1-10%) or negative (0 or < 1%) interpretations and results. Correlation of ER staining

2020 College of American Pathologists

18. Neratinib (Nerlynx) - breast cancer

progression at the end of the study. A 5- year sensitivity analysis was conducted to assess durability of the treatment effect on iDFS and the impact on overall survival. Invasive disease was defined as invasive ipsilateral tumour recurrence, invasive contralateral breast cancer, local or regional invasive recurrence, distant recurrence or death from any cause. A subgroup of patients with HR-positive disease who had completed trastuzumab within 1 year of randomisation represented the licensed population (...) within NHSScotland. Indication under review: for the extended adjuvant treatment of adult patients with early- stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago. In the relevant subgroup of a phase III study neratinib, given less than one year after adjuvant trastuzumab-based therapy, improved invasive disease-free survival in patients with early-stage hormone receptor positive HER2-overexpressed

2020 Scottish Medicines Consortium

19. PD-L1 (Programmed Death Ligand 1) immunohistochemistry (IHC) testing for access to atezolizumab as first line therapy for patients with locally advanced or metastatic triple-negative breast cancer (TNBC)

breast cancer, and there is likely no requirement for most patients to undergo any additional procedures associated with the collection of tumour tissue in order to perform PD-L1 IHC testing. For those with recurrent disease, PD-L1 IHC testing could be performed on archival tumour tissue. However, the Commentary stated that PD-L1 status will differ between the primary tumour and metastases for some patients. Thus, PD-L1 IHC testing should be conducted using new 12 biopsies or surgical tumour samples (...) immune cells (IC) to determine eligibility for treatment with atezolizumab plus a taxane in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC); and • Pharmaceutical Benefits Scheme (PBS) [Authority Required] listing for treatment with atezolizumab plus a taxane for the treatment of patients with unresectable locally advanced or metastatic TNBC who have evidence of PD-L1 expression on IC covering =1% of tumour area. 2. MSAC’s advice to the Minister After

2020 Medical Services Advisory Committee

20. Breast cancer: NCCP guidance for Medical Professionals on the management of patients undergoing Breast Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) outbreak

Breast cancer: NCCP guidance for Medical Professionals on the management of patients undergoing Breast Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) outbreak Version: 1 Department: NCCP Radiation Oncology Working Group Last updated: 01/04/2020 Code: RO_COVID19_1 Date for revision: 15/04/2020 Page 1 of 3 NCCP advice for Medical Professionals on the management of patients undergoing Breast Cancer Radiotherapy in response to the current novel coronavirus (COVID-19 (...) ? DoH Coronavirus (COVID-19) - https://www.gov.ie/en/campaigns/c36c85-covid-19- coronavirus/ ? Ireland’s National Action Plan in response to COVID-19 (Coronavirus) - https://www.gov.ie/en/campaigns/c36c85-covid-19-coronavirus/ 2 Purpose The purpose of this guidance document is to provide guidance to medical professionals on the management of patients undergoing Breast Cancer Radiotherapy during the COVID-19 pandemic. Version: 1 Department: NCCP Radiation Oncology Working Group Last updated: 01/04

2020 Health Service Executive (Ireland) - Clinical Guidelines